Aldeyra Therapeutics Inc Corporate Analyst Meeting Transcript
Okay. Thank you all for joining us today. It's great to see so many of you here. Those of you that know me know that I take great pleasure in R&D days. They allow us to talk about data in ways that we don't typically talk about in standard data releases and press releases and so forth. And there's a lot going on at Aldeyra, as many of you know. And so we're thrilled to be here today and thank you all for coming. And for those of you that are on the webcast, we appreciate your listening in as well.
As always, we do have a forward-looking statement slide, which I encourage you to review, which I will get to when I figure out how to advance the slides here. Good. There we are. Great.
It's hard to believe that some years ago, this company started based on a novel pharmacologic target called RASP. No drugs, no animal models, just an idea and RASP was broadly applicable. And now today, RASP, thanks to the success at Aldeyra, is the subject of numerous Phase III trials. And as of last year, we acquired another
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
